Stopping myeloma maintenance after two years shows no survival loss in trial
medicalxpress - For patients with newly diagnosed multiple myeloma not undergoing an autologous stem cell transplant, indefinite lenalidomide maintenance has long been standard care despite limited evidence to guide the optimal duration of treatment. A randomized phase 3…
AI Summary: Long‑term follow‑up from a randomized multiple myeloma maintenance study indicates that stopping lenalidomide after two years yields similar overall survival to continuing indefinitely. The data support a limited‑duration maintenance strategy that may spare patients toxicity and costs without sacrificing outcomes — revolutionary for weary patients and budget‑conscious oncologists alike.
- Clinicians and advocates react: praise and guidance after ENDURANCE results (6)
- ENDURANCE trial: Two-year lenalidomide equals continuous therapy (3)
Clinicians and advocates react: praise and guidance after ENDURANCE results
ENDURANCE trial: Two-year lenalidomide equals continuous therapy
Related Stories
Two high‑dose radiotherapy sessions safely treat localized prostate cancer / 3 months
ESMO issues new metastatic colorectal cancer clinical guideline / 4 months
Bristol Myers and Hengrui strike up to $15.2B global oncology pact / 3 months
Perioperative advances reshape muscle‑invasive bladder cancer care / 5 wks
Ovarian suppression with tamoxifen cuts recurrence in premenopausal breast cancer / 1 month
Journal retracts study claiming morning immunotherapy benefit / 2 months
Perioperative apalutamide plus ADT improves high‑risk prostate outcomes / 2 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Pancreatic Cancer, Reproductive Health, Price Transparency, Olfaction and look for the RSS link.
StackHealth Time Machine